• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 患者出院后的血栓形成和出血。

Postdischarge thrombosis and hemorrhage in patients with COVID-19.

机构信息

Division of Hematology and.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

出版信息

Blood. 2020 Sep 10;136(11):1342-1346. doi: 10.1182/blood.2020007938.

DOI:10.1182/blood.2020007938
PMID:32766883
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7483433/
Abstract

Coronavirus disease 2019 (COVID-19) is associated with a prothrombotic state with a high incidence of thrombotic events during hospitalization; however, data examining rates of thrombosis after discharge are limited. We conducted a retrospective observational cohort study of discharged patients with confirmed COVID-19 not receiving anticoagulation. The cohort included 163 patients with median time from discharge to last recorded follow-up of 30 days (interquartile range [IQR], 17-46 days). The median duration of index hospitalization was 6 days (IQR, 3-12 days) and 26% required intensive care. The cumulative incidence of thrombosis (including arterial and venous events) at day 30 following discharge was 2.5% (95% confidence interval [CI], 0.8-7.6); the cumulative incidence of venous thromboembolism alone at day 30 postdischarge was 0.6% (95% CI, 0.1-4.6). The 30-day cumulative incidence of major hemorrhage was 0.7% (95% CI, 0.1-5.1) and of clinically relevant nonmajor bleeds was 2.9% (95% CI, 1.0-9.1). We conclude that the rates of thrombosis and hemorrhage appear to be similar following hospital discharge for COVID-19, emphasizing the need for randomized data to inform recommendations for universal postdischarge thromboprophylaxis.

摘要

2019 年冠状病毒病(COVID-19)与促血栓形成状态相关,住院期间血栓事件的发生率较高;然而,关于出院后血栓形成率的数据有限。我们对未接受抗凝治疗的出院确诊 COVID-19 患者进行了回顾性观察性队列研究。该队列包括 163 名患者,从出院到最后一次记录随访的中位时间为 30 天(四分位距 [IQR],17-46 天)。指数住院的中位时间为 6 天(IQR,3-12 天),26%需要重症监护。出院后第 30 天血栓形成(包括动脉和静脉事件)的累积发生率为 2.5%(95%置信区间 [CI],0.8-7.6);出院后第 30 天单纯静脉血栓栓塞的累积发生率为 0.6%(95%CI,0.1-4.6)。30 天主要出血的累积发生率为 0.7%(95%CI,0.1-5.1),临床相关非大出血的累积发生率为 2.9%(95%CI,1.0-9.1)。我们的结论是,COVID-19 患者出院后血栓形成和出血的发生率似乎相似,这强调需要随机数据来为普遍的出院后血栓预防提供建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad4/7483433/b6252de44516/bloodBLD2020007938f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad4/7483433/05dfe2adbb64/bloodBLD2020007938absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad4/7483433/b6252de44516/bloodBLD2020007938f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad4/7483433/05dfe2adbb64/bloodBLD2020007938absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad4/7483433/b6252de44516/bloodBLD2020007938f1.jpg

相似文献

1
Postdischarge thrombosis and hemorrhage in patients with COVID-19.COVID-19 患者出院后的血栓形成和出血。
Blood. 2020 Sep 10;136(11):1342-1346. doi: 10.1182/blood.2020007938.
2
Postdischarge venous thromboembolism following hospital admission with COVID-19.COVID-19 住院后出院后的静脉血栓栓塞症。
Blood. 2020 Sep 10;136(11):1347-1350. doi: 10.1182/blood.2020008086.
3
Factors Associated With Risk of Postdischarge Thrombosis in Patients With COVID-19.与 COVID-19 患者出院后血栓形成风险相关的因素。
JAMA Netw Open. 2021 Nov 1;4(11):e2135397. doi: 10.1001/jamanetworkopen.2021.35397.
4
Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study.COVID-19 重症患者的血栓和出血并发症:一项多中心观察研究。
Crit Care. 2020 Sep 18;24(1):561. doi: 10.1186/s13054-020-03260-3.
5
Bilateral Adrenal Hemorrhage in Coronavirus Disease 2019 Patient: A Case Report.《2019 冠状病毒病患者双侧肾上腺出血:病例报告》。
J Clin Endocrinol Metab. 2020 Dec 1;105(12). doi: 10.1210/clinem/dgaa487.
6
Incidence of Venous Thromboembolism in Critically Ill Coronavirus Disease 2019 Patients Receiving Prophylactic Anticoagulation.新冠肺炎危重症患者预防性抗凝治疗的静脉血栓栓塞症发生率。
Crit Care Med. 2020 Sep;48(9):e805-e808. doi: 10.1097/CCM.0000000000004472.
7
Incidence, clinical course and risk factor for recurrent PCR positivity in discharged COVID-19 patients in Guangzhou, China: A prospective cohort study.中国广州出院的 COVID-19 患者中 PCR 复阳的发生率、临床病程和危险因素:一项前瞻性队列研究。
PLoS Negl Trop Dis. 2020 Aug 31;14(8):e0008648. doi: 10.1371/journal.pntd.0008648. eCollection 2020 Aug.
8
Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience.新冠肺炎肺炎中的血栓并发症和抗凝治疗:纽约市医院的经验。
Ann Hematol. 2020 Oct;99(10):2323-2328. doi: 10.1007/s00277-020-04216-x. Epub 2020 Aug 17.
9
Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications.新型冠状病毒肺炎患者的急性肾损伤:城市内医院的经验及政策影响。
Am J Nephrol. 2020;51(10):786-796. doi: 10.1159/000511160. Epub 2020 Oct 2.
10
Incidence of venous thromboembolism in hospitalized patients with COVID-19.COVID-19 住院患者静脉血栓栓塞症的发生率。
J Thromb Haemost. 2020 Aug;18(8):1995-2002. doi: 10.1111/jth.14888. Epub 2020 Jul 27.

引用本文的文献

1
The Prevalence of Previous Coronavirus Disease-19 in Patients with Pulmonary Thromboembolism and Its Effect on Embolism Severity.肺血栓栓塞症患者中既往冠状病毒病-19的患病率及其对栓塞严重程度的影响。
J Clin Med. 2025 Mar 12;14(6):1909. doi: 10.3390/jcm14061909.
2
COVID-19-Related Spinal Subdural Hematoma Presented with Acute Compressive Myelopathy with a Review of the Literature.新型冠状病毒肺炎相关的脊髓硬膜下血肿伴急性压迫性脊髓病并文献复习
Case Rep Neurol. 2024 Nov 29;16(1):294-303. doi: 10.1159/000528310. eCollection 2024 Jan-Dec.
3
American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary.

本文引用的文献

1
Emergence of institutional antithrombotic protocols for coronavirus 2019.2019冠状病毒病机构性抗血栓形成方案的出现。
Res Pract Thromb Haemost. 2020 Jun 12;4(4):510-517. doi: 10.1002/rth2.12358. eCollection 2020 May.
2
Coronavirus Disease 2019 Coagulopathy: Disseminated Intravascular Coagulation and Thrombotic Microangiopathy-Either, Neither, or Both.2019冠状病毒病凝血障碍:弥散性血管内凝血和血栓性微血管病——是其一、均不是或两者皆是。
Semin Thromb Hemost. 2020 Oct;46(7):781-784. doi: 10.1055/s-0040-1712156. Epub 2020 Jun 8.
3
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection.
美国血液学会关于COVID-19患者血栓预防抗凝治疗的实用指南:执行摘要
Blood Adv. 2025 Mar 25;9(6):1247-1260. doi: 10.1182/bloodadvances.2024014219.
4
Vascular Pathogenesis in Acute and Long COVID: Current Insights and Therapeutic Outlook.急性和长期新冠病毒感染中的血管发病机制:当前见解与治疗前景
Semin Thromb Hemost. 2025 Apr;51(3):256-271. doi: 10.1055/s-0044-1790603. Epub 2024 Sep 30.
5
Symptomatic Venous Thromboembolic Events in COVID-19 Patients after Hospital Discharge: Aspects to Consider.新冠病毒感染患者出院后有症状的静脉血栓栓塞事件:需考虑的方面
Rev Cardiovasc Med. 2022 Jun 20;23(6):219. doi: 10.31083/j.rcm2306219. eCollection 2022 Jun.
6
Multidisciplinary Management Strategies for Long COVID: A Narrative Review.长新冠的多学科管理策略:一项叙述性综述
Cureus. 2024 May 1;16(5):e59478. doi: 10.7759/cureus.59478. eCollection 2024 May.
7
Mechanisms of Pulmonary Vasculopathy in Acute and Long-Term COVID-19: A Review.急性和长期 COVID-19 中的肺血管病机制:综述。
Int J Mol Sci. 2024 Apr 30;25(9):4941. doi: 10.3390/ijms25094941.
8
Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxis.新型冠状病毒肺炎住院期间及出院后的血栓栓塞并发症:发病率、危险因素及血栓预防
Thromb Update. 2022 Mar;6:100096. doi: 10.1016/j.tru.2021.100096. Epub 2022 Jan 3.
9
Mortality, critical illness, and mechanical ventilation among hospitalized patients with COVID-19 on therapeutic anticoagulants.接受治疗性抗凝治疗的COVID-19住院患者的死亡率、重症疾病及机械通气情况。
Thromb Update. 2021;2:100027. doi: 10.1016/j.tru.2020.100027. Epub 2021 Mar 19.
10
Predicting drug outcome of population via clinical knowledge graph.通过临床知识图谱预测人群的药物疗效。
medRxiv. 2024 Oct 19:2024.03.06.24303800. doi: 10.1101/2024.03.06.24303800.
COVID-19 和凝血:SARS-CoV-2 感染的出血和血栓形成表现。
Blood. 2020 Jul 23;136(4):489-500. doi: 10.1182/blood.2020006520.
4
Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum.COVID-19 大流行期间的血栓栓塞和抗凝治疗:抗凝论坛的临时临床指南。
J Thromb Thrombolysis. 2020 Jul;50(1):72-81. doi: 10.1007/s11239-020-02138-z.
5
Where do we stand with antithrombotic prophylaxis in patients with COVID-19?对于新冠肺炎患者的抗血栓预防,我们目前处于什么阶段?
Thromb Res. 2020 Jul;191:29. doi: 10.1016/j.thromres.2020.04.023. Epub 2020 Apr 20.
6
COVID-19: towards understanding of pathogenesis.新型冠状病毒肺炎:对发病机制的认识
Cell Res. 2020 May;30(5):367-369. doi: 10.1038/s41422-020-0327-4.
7
COVID-19 and its implications for thrombosis and anticoagulation.新型冠状病毒肺炎及其对血栓形成和抗凝的影响。
Blood. 2020 Jun 4;135(23):2033-2040. doi: 10.1182/blood.2020006000.
8
ISTH interim guidance on recognition and management of coagulopathy in COVID-19.国际血栓与止血学会(ISTH)关于新冠病毒病(COVID-19)凝血病识别与管理的临时指南。
J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27.
9
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.新型冠状病毒肺炎与血栓栓塞性疾病:预防、抗栓治疗与随访的相关问题:美国心脏病学会临床实践更新。
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17.
10
American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.美国血液学会 2019 年静脉血栓栓塞症管理指南:手术住院患者静脉血栓栓塞症的预防。
Blood Adv. 2019 Dec 10;3(23):3898-3944. doi: 10.1182/bloodadvances.2019000975.